Quarterly ResultMay 14, 2026, 04:31 PM
MapLight Therapeutics Q1 Net Loss $(60.7)M; R&D up 171%
AI Summary
MapLight Therapeutics reported a net loss of $(60.7) million for Q1 2026, a significant increase from $(22.3) million in Q1 2025, driven by a 171% rise in research and development expenses. The clinical-stage biopharmaceutical company's operating expenses more than doubled. Despite the increased cash burn, the company maintains a strong liquidity position with $395.2 million in cash and investments, expected to fund operations for at least 12 months following its October 2025 IPO.
Key Highlights
- Net loss for Q1 2026 was $(60.7) million, compared to $(22.3) million in Q1 2025.
- Research and development expenses increased to $53.7 million in Q1 2026, up 171% YoY.
- General and administrative expenses rose to $10.8 million in Q1 2026, up from $3.8 million YoY.
- Net cash used in operating activities was $(51.2) million in Q1 2026.
- Cash, cash equivalents, and investments totaled $395.2 million as of March 31, 2026.
- Accumulated deficit reached $(421.2) million as of March 31, 2026.
- Stock-based compensation expense was $9.6 million in Q1 2026.
Price Impact
More from MPLT